Takeda Pharmaceutical Co ADR (NYSE: TAK) started the day on Wednesday, with a price increase of 0.78% at $15.58, before settling in for the price of $15.46 at the close. Taking a more long-term approach, TAK posted a 52-week range of $12.80-$15.69.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 11.40%. Meanwhile, its Annual Earning per share during the time was 11.40%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 53.47%. This publicly-traded company’s shares outstanding now amounts to $3.16 billion, simultaneously with a float of $3.16 billion. The organization now has a market capitalization sitting at $49.22 billion. At the time of writing, stock’s 50-day Moving Average stood at $14.20, while the 200-day Moving Average is $14.65.
Takeda Pharmaceutical Co ADR (TAK) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Drug Manufacturers – Specialty & Generic Industry. Takeda Pharmaceutical Co ADR’s current insider ownership accounts for 0.00%, in contrast to 2.71% institutional ownership.
Takeda Pharmaceutical Co ADR (TAK) Earnings and Revenue Records
Takeda Pharmaceutical Co ADR’s EPS increase for this current 12-month fiscal period is 53.47% and is forecasted to reach 0.61 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 42.50% through the next 5 years, which can be compared against the 11.40% growth it accomplished over the previous five years trading on the market.
Takeda Pharmaceutical Co ADR (NYSE: TAK) Trading Performance Indicators
Let’s observe the current performance indicators for Takeda Pharmaceutical Co ADR (TAK). It’s Quick Ratio in the last reported quarter now stands at 0.76. Alongside those numbers, its PE Ratio stands at $197.72, and its Beta score is 0.06. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.66. Similarly, its price to free cash flow for trailing twelve months is now 7.99.
In the same vein, TAK’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.08, a figure that is expected to reach 0.17 in the next quarter, and analysts are predicting that it will be 0.61 at the market close of one year from today.
Technical Analysis of Takeda Pharmaceutical Co ADR (TAK)
If we take a close look at the recent performances of Takeda Pharmaceutical Co ADR (NYSE: TAK), its last 5-days Average volume was 3.79 million that shows progress from its year to date volume of 2.67 million. During the previous 9 days, stock’s Stochastic %D was recorded 96.29% While, its Average True Range was 85.46.
Raw Stochastic average of Takeda Pharmaceutical Co ADR (TAK) in the period of the previous 100 days is set at 95.93%, which indicates a major fall in contrast to 97.26% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.17 that was higher than 0.15 volatility it exhibited in the past 100-days period.
